Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADILNASDAQ:ALLRNASDAQ:BCTXNASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$0.23-12.8%$0.60$0.22▼$3.00$2.74M1.181.46 million shs57.87 million shsALLRAllarity Therapeutics$1.05+16.7%$0.98$0.61▼$10.59$13.57M-0.151.13 million shs1.41 million shsBCTXBriacell Therap$2.97+3.1%$3.63$2.78▼$29.40$19.51M1.3568,593 shs4.06 million shsQNTMQuantum Biopharma$27.13+17.9%$12.54$2.70▼$38.25$66.90M0.55945,855 shs620,606 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals+7.17%-19.10%-61.87%-62.96%-76.52%ALLRAllarity Therapeutics-3.23%+7.90%-12.62%-18.92%-93.27%BCTXBriacell Therap-5.88%-8.86%-6.19%-29.58%-83.93%QNTMQuantum Biopharma-34.26%+7.27%+99.22%+292.66%+2,300,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial Pharmaceuticals2.8445 of 5 stars3.85.00.00.00.60.01.3ALLRAllarity TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABCTXBriacell Therap1.5286 of 5 stars3.52.00.00.01.10.00.6QNTMQuantum BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial Pharmaceuticals 3.50Strong Buy$8.003,388.88% UpsideALLRAllarity Therapeutics 0.00N/AN/AN/ABCTXBriacell Therap 3.00Buy$32.00977.44% UpsideQNTMQuantum Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ADIL, QNTM, BCTX, and ALLR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025QNTMQuantum BiopharmaSingular ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy4/22/2025BCTXBriacell TherapHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$0.64 per shareN/AALLRAllarity TherapeuticsN/AN/AN/AN/A$1.62 per shareN/ABCTXBriacell TherapN/AN/AN/AN/A$1.76 per shareN/AQNTMQuantum BiopharmaN/AN/AN/AN/A$4.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$13.20M-$1.46N/AN/AN/AN/A-218.88%-177.61%8/12/2025 (Estimated)ALLRAllarity Therapeutics-$24.51MN/A0.00N/AN/AN/A-147.94%-90.33%8/4/2025 (Estimated)BCTXBriacell Therap-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%N/AQNTMQuantum Biopharma-$14.20M-$15.98N/AN/AN/AN/A-155.20%-94.90%8/13/2025 (Estimated)Latest ADIL, QNTM, BCTX, and ALLR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/13/2025Q3 2025BCTXBriacell Therap-$1.76-$1.64+$0.12-$1.64N/AN/A5/14/2025Q1 2025ADILAdial Pharmaceuticals-$0.50-$0.34+$0.16-$0.34N/AN/A5/14/2025Q1 2025QNTMQuantum Biopharma-$0.37-$1.41-$1.04-$3.53$2.09 million$2.09 million5/13/2025Q1 2025ALLRAllarity Therapeutics-$8.10-$0.25+$7.85-$0.25N/AN/A3/28/2025Q4 2024QNTMQuantum Biopharma-$0.80-$2.89-$2.09-$2.89$0.92 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/AALLRAllarity TherapeuticsN/AN/AN/AN/AN/ABCTXBriacell TherapN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A1.991.99ALLRAllarity TherapeuticsN/A2.662.66BCTXBriacell TherapN/A3.413.41QNTMQuantum BiopharmaN/A0.960.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%ALLRAllarity Therapeutics11.53%BCTXBriacell Therap15.42%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals4.26%ALLRAllarity Therapeutics0.01%BCTXBriacell Therap5.73%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals2010.44 million9.99 millionNo DataALLRAllarity Therapeutics1015.08 million15.08 millionNot OptionableBCTXBriacell Therap86.78 million6.39 millionOptionableQNTMQuantum BiopharmaN/A2.91 million2.66 millionN/AADIL, QNTM, BCTX, and ALLR HeadlinesRecent News About These CompaniesQ1 Earnings Forecast for QNTM Issued By Singular ResearchJune 24 at 1:41 AM | americanbankingnews.comTop Cannabis Stocks To Keep An Eye On - June 23rdJune 23 at 2:09 PM | marketbeat.comWhat is Singular Research's Estimate for QNTM Q1 Earnings?June 23 at 1:36 AM | marketbeat.comQuantum Biopharma (NASDAQ:QNTM) Upgraded at Singular ResearchJune 21 at 5:59 AM | marketbeat.comCannabis Stocks To Follow Today - June 20thJune 20, 2025 | marketbeat.comUnbuzzd Wellness Inc Ordinary Shares - Class B (Sub Voting)June 19, 2025 | morningstar.comQuantum, CyberCatch, Kodiak at 52-Week Highs on NewsJune 18, 2025 | ca.finance.yahoo.comSingular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline ProgressJune 18, 2025 | newsfilecorp.comKeg, LQWD, Quantum at 52-Week Highs on NewsJune 17, 2025 | baystreet.caCannabis Stocks To Add to Your Watchlist - June 17thJune 17, 2025 | marketbeat.comQuantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General HospitalJune 17, 2025 | globenewswire.comQuantum BioPharma plans special dividend tied to legal actionJune 14, 2025 | investing.comBest Cannabis Stocks To Add to Your Watchlist - June 13thJune 13, 2025 | marketbeat.comQuantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement ProceedsJune 13, 2025 | globenewswire.comQuantum BioPharma Boosts Digital Asset Holdings to $5 Million with New Bitcoin PurchaseJune 10, 2025 | bitcoinmagazine.comQuantum BioPharma clarifies misinformation on stock name, RTO rumorsJune 4, 2025 | investing.comQuantum BioPharma Clarifies Name Confusion, Refutes RTO Rumors With Unbuzzd WellnessJune 4, 2025 | nasdaq.comQuantum BioPharma Clarifies It Has Not Changed Its NameJune 3, 2025 | globenewswire.comiNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS PatientsJune 2, 2025 | globenewswire.comQuantum BioPharma settles disputes with former CEOJune 1, 2025 | uk.investing.comWhat's Going On With Quantum Biopharma Stock Today?May 30, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADIL, QNTM, BCTX, and ALLR Company DescriptionsAdial Pharmaceuticals NASDAQ:ADIL$0.23 -0.03 (-12.81%) Closing price 04:00 PM EasternExtended Trading$0.23 +0.00 (+0.74%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Allarity Therapeutics NASDAQ:ALLR$1.05 +0.15 (+16.67%) Closing price 04:00 PM EasternExtended Trading$1.05 0.00 (0.00%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Briacell Therap NASDAQ:BCTX$2.97 +0.09 (+3.13%) Closing price 04:00 PM EasternExtended Trading$2.97 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Quantum Biopharma NASDAQ:QNTM$27.13 +4.12 (+17.91%) Closing price 04:00 PM EasternExtended Trading$27.42 +0.29 (+1.08%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
